MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer
Author(s)
Han, Sangyoon; Jonas, Oliver; Oudin, Madeleine Julie; Barbier, Lucie; Schafer, Claudia; Kosciuk, Tatsiana; Miller, Miles Aaron; Lauffenburger, Douglas A; Gertler, Frank; ... Show more Show less![Thumbnail](/bitstream/handle/1721.1/116423/nihms827549.pdf.jpg?sequence=6&isAllowed=y)
Downloadnihms827549.pdf (2.434Mb)
OPEN_ACCESS_POLICY
Open Access Policy
Creative Commons Attribution-Noncommercial-Share Alike
Terms of use
Metadata
Show full item recordAbstract
Taxane therapy remains the standard of care for triple-negative breast cancer. However, high frequencies of recurrence and progression in treated patients indicate that metastatic breast cancer cells can acquire resistance to this drug. The actin regulatory protein MENA and particularly its invasive isoform, MENAINV , are established drivers of metastasis. MENAINV expression is significantly correlated with metastasis and poor outcome in human patients with breast cancer. We investigated whether MENA isoforms might play a role in driving resistance to chemotherapeutics. We find that both MENA and MENAINV confer resistance to the taxane paclitaxel, but not to the widely used DNA-damaging agents doxorubicin or cisplatin. Furthermore, paclitaxel treatment does not attenuate growth of MENAINV -driven metastatic lesions. Mechanistically, MENA isoform expression alters the ratio of dynamic and stable microtubule populations in paclitaxel-treated cells. MENA expression also increases MAPK signaling in response to paclitaxel treatment. Decreasing ERK phosphorylation by cotreatment with MEK inhibitor restored paclitaxel sensitivity by driving microtubule stabilization in MENA isoform-expressing cells. Our results reveal a novel mechanism of taxane resistance in highly metastatic breast cancer cells and identify a combination therapy to overcome such resistance.
Date issued
2016-11Department
Massachusetts Institute of Technology. Department of Biological Engineering; Massachusetts Institute of Technology. Department of Biology; Koch Institute for Integrative Cancer Research at MITJournal
Molecular Cancer Therapeutics
Publisher
American Association for Cancer Research (AACR)
Citation
Oudin, Madeleine J. et al. “MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer.” Molecular Cancer Therapeutics 16, 1 (November 2016): 143–155 © 2016 American Association for Cancer Research
Version: Author's final manuscript
ISSN
1535-7163
1538-8514